Washington – – September 15, 2026 -- Clearsight Advisors served as exclusive sell-side advisor to Ambit RD, Inc. on its acquisition by Danforth Health, Inc., a portfolio company of Avesi Partners, in a deal announced by the firms.
Ambit brings patient-identification technology to Danforth's life sciences platform
Ambit RD specializes in commercial strategy, advanced analytics, and patient identification solutions for rare and specialty biopharma markets, operating through three service lines: Strategic Services, Analytics & Data Services, and Patient ID Services. The company helps biopharmaceutical organizations locate patients, speed therapy adoption, and engage healthcare providers across the clinical and commercial continuum.
Danforth expands via acquisition strategy backed by Avesi Partners
Danforth Health provides business, clinical, and commercial solutions supporting life sciences companies from product development through commercialization. The Avesi-backed platform has pursued strategic acquisitions to broaden its service offerings across the life sciences ecosystem, with Ambit's capabilities now integrated into that platform.
Ambit executives cite shared vision on rare disease patient outcomes
Rob Sederman, Co-Founder and CEO of Ambit, said finding a partner aligned with the company's mission to serve rare and specialty disease populations was central to the deal, crediting Clearsight's execution support for the outcome. Ned Kitfield, Co-Founder and Chief Commercial Officer, said the combination positions Ambit to accelerate innovation and expand support across the product lifecycle.
Clearsight advisors point to rising demand for specialized commercialization partners
Tory Steel, Managing Director at Clearsight Advisors, said Ambit's combination of consulting, analytics, and patient-focused solutions has created a differentiated platform within the rare and specialty disease market. Austin Kuhn, Director at Clearsight, said the transaction reflects broader life sciences demand for specialized partners addressing complex commercialization and patient engagement challenges. The Clearsight deal team included Tory Steel, Greg Treger, Austin Kuhn, Jake Kohlbrenner, Grace Bryant, and William Trukenbrod.